Early Alert: Blood Pump Controller Issue from Abiomed
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Italiano
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) - including certain formulations of amphetamine and methylphenidate - to warn about the risk of weight loss and other adverse reactions (side effects) in patients yo
Traitement d'urgence des réactions allergiques de type I, dont l'anaphylaxie, chez l'adulte et l'enfant pesant au moins 30 kg.
Sandoz, Inc. (“Sandoz”) is initiating a voluntary recall of one (1) lot of Cefazolin for Injection, USP, 1 gram per vial.
Dans le traitement de la cholestase intrahépatique familiale chez les personnes atteintes âgées de 3 ans et plus.
Affected device lots may experience tip separation; field complaints reported that the tip separation can occur both prior to and during patient contact.
mRNA COVID-19 Vaccines: FDA Safety Communication - FDA Approves Required Updated Warning in Labeling Regarding Myocarditis and Pericarditis Following Vaccination
80.211.154.110